These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 121849)

  • 21. [Efficacy of multidrug therapy in treatment of paucibacillary leprosy patients--preliminary results].
    Avelleira JC; Marques AB; Viana FR; de Andrade VL
    Hansenol Int; 1989 Dec; 14(2):107-11. PubMed ID: 2562587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of sulphone resistant leprosy--a review of sixty one cases.
    Seshadri PS; Ravi NT
    Lepr India; 1982 Oct; 54(4):639-47. PubMed ID: 6191123
    [No Abstract]   [Full Text] [Related]  

  • 23. [2 cases of recurrence resistant to rifampicin in lepromatous leprosy].
    Cottenot F; Wallach D; Flageul B; Pennec J; Wastiaux K
    Ann Dermatol Venereol; 1983; 110(9):703-4. PubMed ID: 6660769
    [No Abstract]   [Full Text] [Related]  

  • 24. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro immunologic changes in 7 patients with lepromatous leprosy and borderline leprosy treated with levamisole].
    Saint-André P; Travi Piacentile M; Baquillon G; Ferracci C
    Acta Leprol; 1979; (76-77):295-300. PubMed ID: 121848
    [No Abstract]   [Full Text] [Related]  

  • 26. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
    Gelber RH; Humphres RC; Fieldsteel AH
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of probenecid on serum rifampicin levels.
    Pankaj R; Lal S; Rao RS
    Indian J Lepr; 1985; 57(2):329-33. PubMed ID: 4078358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A survey of the drugs with activity against M. leprae in mice.
    Shepard CC
    Int J Lepr Other Mycobact Dis; 1971; 39(2):340-8. PubMed ID: 4948080
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of rifampicin for leprosy: comparative study with several doses and intervals of administration.
    Namba M; Hazama S
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):198. PubMed ID: 945236
    [No Abstract]   [Full Text] [Related]  

  • 31. Ultrastructural alterations of mycobacterium leprae in skin biopsies of untreated and treated lepromatous patients.
    Silva MT; Macedo PM; Costa MH; Gonçalves H; Torgal J; David HL
    Ann Microbiol (Paris); 1982; 133(1):75-92. PubMed ID: 7051933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Streptomycin combined with sulfones in the treatment of relapsed lepromatous leprosy.
    Hastings RC; Trautman JR
    Int J Lepr Other Mycobact Dis; 1968; 36(1):45-51. PubMed ID: 5689649
    [No Abstract]   [Full Text] [Related]  

  • 33. Follow-up study of pauci-bacillary leprosy on-multi-drug regimen.
    Ramanan R; Manglani PR; Ghorpade A; Bhagoliwal SK
    Indian J Lepr; 1987; 59(1):50-3. PubMed ID: 3611861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of the efficacy of WHO and IAL multidrug therapy regimens for leprosy--an in-vivo and in-vitro study.
    Revankar CR; Mahadevan PR; Ganapati R
    Indian J Lepr; 1986; 58(4):543-8. PubMed ID: 3553361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immuno-allergic accidents with rifamipcin].
    Flageul B; Wagner L; Cottenot F
    Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current status of the medical treatment of Hansen's disease].
    Coudert J; Lu HT
    J Med Lyon; 1972 Sep; 53(232):1047-54. PubMed ID: 4638074
    [No Abstract]   [Full Text] [Related]  

  • 38. Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient.
    Kar HK; Roy RG
    Indian J Lepr; 1984; 56(4):835-9. PubMed ID: 6549453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal)].
    Grosset J; Guelpa-Lauras CC; Millan J; Bodian M; Perani E
    Med Trop (Mars); 1987; 47(2):171-5. PubMed ID: 3306248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial with rifampicin in the treatment of leprosy (final report).
    Ghosh S; Hazra SK; Kundu S; Choudhury S
    Lepr India; 1977 Jul; 49(3):339-43. PubMed ID: 338983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.